dc.contributor |
Darido, Charbel |
|
dc.date |
2022-09-16T13:47:14Z |
|
dc.date |
2022-09-16T13:47:14Z |
|
dc.date |
2022 |
|
dc.date.accessioned |
2023-02-18T19:28:57Z |
|
dc.date.available |
2023-02-18T19:28:57Z |
|
dc.identifier |
ONIX_20220916_9783036547589_83 |
|
dc.identifier |
https://directory.doabooks.org/handle/20.500.12854/92097 |
|
dc.identifier |
https://mdpi.com/books/pdfview/book/5974 |
|
dc.identifier |
https://mdpi.com/books/pdfview/book/5974 |
|
dc.identifier.uri |
http://localhost:8080/xmlui/handle/CUHPOERS/249589 |
|
dc.description |
Squamous cell cancer (SCC) development and recent preclinical and clinical advances for the effective prevention and treatment of the disease are covered in this book. Experts in the field describe here the cellular and molecular events in SCC development, recurrence, and metastasis, and provide an updated snapshot on our understanding of the heterogeneity of SCC pathogenesis with novel opportunities in precision therapeutics to achieve better clinical outcomes. |
|
dc.format |
application/octet-stream |
|
dc.language |
eng |
|
dc.publisher |
MDPI Books |
|
dc.rights |
open access |
|
dc.subject |
n/a |
|
dc.subject |
oral cancer |
|
dc.subject |
tobacco |
|
dc.subject |
alcohol |
|
dc.subject |
human papilloma virus |
|
dc.subject |
targeted sequencing |
|
dc.subject |
DNA copy number |
|
dc.subject |
TP53 |
|
dc.subject |
CDKN2A |
|
dc.subject |
EGFR |
|
dc.subject |
PIK3CA |
|
dc.subject |
anal cancer |
|
dc.subject |
radiation therapy |
|
dc.subject |
chemoradiation |
|
dc.subject |
de-escalation of therapy |
|
dc.subject |
pain |
|
dc.subject |
cathepsin S |
|
dc.subject |
protease-activated receptor-2 |
|
dc.subject |
PAR2 |
|
dc.subject |
cancer pain |
|
dc.subject |
oral squamous cell carcinoma |
|
dc.subject |
differentiation |
|
dc.subject |
terminal differentiation |
|
dc.subject |
oral epithelium |
|
dc.subject |
epithelial integrity |
|
dc.subject |
epithelial transformation |
|
dc.subject |
genetic alterations |
|
dc.subject |
therapy response biomarkers |
|
dc.subject |
cutaneous squamous cell carcinoma |
|
dc.subject |
immunotherapy |
|
dc.subject |
anti-PD1 |
|
dc.subject |
biomarkers |
|
dc.subject |
predictive medicine |
|
dc.subject |
personalized medicine |
|
dc.subject |
cancer |
|
dc.subject |
immune system |
|
dc.subject |
HNSCC |
|
dc.subject |
farnesyl transferase |
|
dc.subject |
tipifarnib |
|
dc.subject |
combination regimen |
|
dc.subject |
oropharynx |
|
dc.subject |
neoplasm |
|
dc.subject |
squamous cell carcinoma |
|
dc.subject |
human papillomavirus |
|
dc.subject |
therapeutic management |
|
dc.subject |
treatment selection |
|
dc.subject |
CSCC |
|
dc.subject |
treatment |
|
dc.subject |
advances |
|
dc.subject |
biology |
|
dc.subject |
immunocompromised |
|
dc.subject |
immune checkpoint inhibition |
|
dc.subject |
bic Book Industry Communication::M Medicine |
|
dc.subject |
bic Book Industry Communication::M Medicine::MJ Clinical & internal medicine::MJC Diseases & disorders::MJCL Oncology |
|
dc.title |
Treatments for Squamous Cell Cancer |
|
dc.resourceType |
book |
|
dc.alternateIdentifier |
9783036547589 |
|
dc.alternateIdentifier |
9783036547572 |
|
dc.alternateIdentifier |
10.3390/books978-3-0365-4757-2 |
|
dc.licenseCondition |
Attribution 4.0 International |
|
dc.identifierdoi |
10.3390/books978-3-0365-4757-2 |
|
dc.relationisPublishedBy |
430a2802-f250-43a2-9a76-b343750a1dfa |
|
dc.relationisbn |
9783036547589 |
|
dc.relationisbn |
9783036547572 |
|
dc.pages |
168 |
|
dc.placepublication |
Basel |
|